53156257 Relationship Between Bond Strength Tests and Clinical Outcomes
Point of Care Tests: Clinical Use in 2017 in...Point of Care Tests: Clinical Use in 2017 Charlotte...
Transcript of Point of Care Tests: Clinical Use in 2017 in...Point of Care Tests: Clinical Use in 2017 Charlotte...
![Page 1: Point of Care Tests: Clinical Use in 2017 in...Point of Care Tests: Clinical Use in 2017 Charlotte A. Gaydos, MS, MPH, DrPH Professor, Division of Infectious Diseases. Johns Hopkins](https://reader034.fdocuments.in/reader034/viewer/2022042104/5e823594edeb421cd63ca650/html5/thumbnails/1.jpg)
Point of Care Tests: Clinical Use in 2017
Charlotte A. Gaydos, MS, MPH, DrPHProfessor, Division of Infectious Diseases
Johns Hopkins University, Baltimore, Maryland
Helsinki 31st IUSTI-Europe Congress on STIs
![Page 2: Point of Care Tests: Clinical Use in 2017 in...Point of Care Tests: Clinical Use in 2017 Charlotte A. Gaydos, MS, MPH, DrPH Professor, Division of Infectious Diseases. Johns Hopkins](https://reader034.fdocuments.in/reader034/viewer/2022042104/5e823594edeb421cd63ca650/html5/thumbnails/2.jpg)
Objectives
1. To discuss current molecular tests and update new POC tests in the pipeline
2. To demonstrate different venues for STI testing outside the clinic, OTC or home STI testing
3. To mention impact of POC testing-advantages and barriers
![Page 3: Point of Care Tests: Clinical Use in 2017 in...Point of Care Tests: Clinical Use in 2017 Charlotte A. Gaydos, MS, MPH, DrPH Professor, Division of Infectious Diseases. Johns Hopkins](https://reader034.fdocuments.in/reader034/viewer/2022042104/5e823594edeb421cd63ca650/html5/thumbnails/3.jpg)
0
20
40
60
80
100
120
140
160
Chlamydia Gonorrhea Trichomonas143 Syphilis
131 Million
78 Million
143 Million
6 Million
WHO Estimates of Global Prevalence of STIs in 2012
Newman et al. PLOS ONE | OI:10.1371/journal.pone.0143304 December 8, 2015 7 /
36.7 million Adults and Children Living with HIV
![Page 4: Point of Care Tests: Clinical Use in 2017 in...Point of Care Tests: Clinical Use in 2017 Charlotte A. Gaydos, MS, MPH, DrPH Professor, Division of Infectious Diseases. Johns Hopkins](https://reader034.fdocuments.in/reader034/viewer/2022042104/5e823594edeb421cd63ca650/html5/thumbnails/4.jpg)
Use of POC in Clinical Settings• Immediate treatment before patient
leaves the clinic; no loss to follow-up
• Impact on disease epidemic?– Decrease interval of disease spread
• Impact on behavior?– Counseling on risk reduction
• ASSURED Criteria – When is a test good enough?
![Page 5: Point of Care Tests: Clinical Use in 2017 in...Point of Care Tests: Clinical Use in 2017 Charlotte A. Gaydos, MS, MPH, DrPH Professor, Division of Infectious Diseases. Johns Hopkins](https://reader034.fdocuments.in/reader034/viewer/2022042104/5e823594edeb421cd63ca650/html5/thumbnails/5.jpg)
Affordable by those at risk of infection
Sensitive few false negatives
Specific few false positives
User-friendly simple to perform: 3-4 steps, with minimal training
Rapid and Robustrapid: to enable treatment at first visitrobust: no requirement refrigerated storage
Equipment-free easily collected non-invasive specimens, e.g. urine, saliva. vaginal
Delivered delivered to end-usershttp://www.who.int/std_diagnostics/about_SDI/priorities.htm
WHO ASSURED Criteria for POC Tests
![Page 6: Point of Care Tests: Clinical Use in 2017 in...Point of Care Tests: Clinical Use in 2017 Charlotte A. Gaydos, MS, MPH, DrPH Professor, Division of Infectious Diseases. Johns Hopkins](https://reader034.fdocuments.in/reader034/viewer/2022042104/5e823594edeb421cd63ca650/html5/thumbnails/6.jpg)
Overview: Point-of-Care Tests for STIs
Chlamydia trachomatis (CT)Neisseria gonorrhoeae (NG)Trichomonas vaginalis (TV)SyphilisHerpes Simples Virus (HSV)HIV
Gaydos, C. Rapid Tests for STDs Current Infect Dis Reports 2006;8:115-124
Huppert et al. Point of Care tests for STIs: What’s the Point? Point of Care Journal, 2009
Gaydos and Hardick POC diagnostics for sex transmit infect: Perspectives and advances. Expert Review of Anti-infective Therapy. 12:657-672, 2014.
![Page 7: Point of Care Tests: Clinical Use in 2017 in...Point of Care Tests: Clinical Use in 2017 Charlotte A. Gaydos, MS, MPH, DrPH Professor, Division of Infectious Diseases. Johns Hopkins](https://reader034.fdocuments.in/reader034/viewer/2022042104/5e823594edeb421cd63ca650/html5/thumbnails/7.jpg)
•Chlamydia
•Gonorrhea
•Trichomonas
•Syphilis
•HSV HIV
Overview New POC tests for STIs
Gaydos and Hardick, POC diagnostics for sex transmit infect: Perspectives and advances. Expert Review of Anti-infective Therapy. 12:657-672, 2014.
![Page 8: Point of Care Tests: Clinical Use in 2017 in...Point of Care Tests: Clinical Use in 2017 Charlotte A. Gaydos, MS, MPH, DrPH Professor, Division of Infectious Diseases. Johns Hopkins](https://reader034.fdocuments.in/reader034/viewer/2022042104/5e823594edeb421cd63ca650/html5/thumbnails/8.jpg)
Organism Test Sample Type Sensitivity* Specificity*
Chlamydia trachomatis Biostar OIA Chlamydia test Cervical Male Urine
59.4-73.8% 98.4-100%
Clearview Chlamydia CervicalVaginal
49.7%32.8%
97.9%99.2%
Quick Vue Cervical 25-65% 100%Chlamydia Rapid Test Vaginal
Male Urine83.5% 98.9%
X-pert CT/NG CervicalVaginalFemale UrineMale Urine
97.4%98.7%97.6%97.8%
99.6%99.4%99.8%99.9%
Neisseria gonorrhoeae Biostar OIA GC test Cervical 60% 89.9%PATH GC-Check Cervical
Vaginal70%54.1%
97.2%98.25
X-pert CT/NG CervicalVaginalFemale UrineMale Urine
100%100%95.6%98.9%
100%99.9%99.9%99.9%
Sensitivity and Specificity of POC/near patient tests for CT & NG
Gaydos and Hardick POC diagnostics for sex transmit infect: Perspectives and advances. Expert Reviews 10.1586/147872.2014.880651, 2014 Adapted from Huppert et al. (2010). * Sensitivity and specificity compared to NAATs
![Page 9: Point of Care Tests: Clinical Use in 2017 in...Point of Care Tests: Clinical Use in 2017 Charlotte A. Gaydos, MS, MPH, DrPH Professor, Division of Infectious Diseases. Johns Hopkins](https://reader034.fdocuments.in/reader034/viewer/2022042104/5e823594edeb421cd63ca650/html5/thumbnails/9.jpg)
“Near Patient” Test for Chlamydia and
Gonorrhea
GeneXpert® CT/NG, Cepheid (90 minutes)
Gaydos et al. J Clin Microbiol. 51:1666-1672, 2013
Sensitivity: 95-100%Specificity 99-100%
FDA Cleared: CT/NG,TV; urine, cervical, vaginal swabs
![Page 10: Point of Care Tests: Clinical Use in 2017 in...Point of Care Tests: Clinical Use in 2017 Charlotte A. Gaydos, MS, MPH, DrPH Professor, Division of Infectious Diseases. Johns Hopkins](https://reader034.fdocuments.in/reader034/viewer/2022042104/5e823594edeb421cd63ca650/html5/thumbnails/10.jpg)
Female Results CT/NGXpert CT/NG vs. Patient Infected Status
Specimen Sensitivity SpecificityCT Cervical 97.4% 99.6%
CT Vaginal 98.7% 99.4%CT Urine 97.6% 99.8%NG Cervical 100% 100%NG Vaginal 100% 99.9%
NG Urine 95.6% 99.9%Gaydos et al. J Clin Microbiol. 51:1666-1672, 2013
![Page 11: Point of Care Tests: Clinical Use in 2017 in...Point of Care Tests: Clinical Use in 2017 Charlotte A. Gaydos, MS, MPH, DrPH Professor, Division of Infectious Diseases. Johns Hopkins](https://reader034.fdocuments.in/reader034/viewer/2022042104/5e823594edeb421cd63ca650/html5/thumbnails/11.jpg)
Male Results
Xpert CT/NG vs. Patient Infected Status
Specimen Sensitivity Specificity
CT Urine 97.5% 99.9%NG Urine 98.9% 99.9%
![Page 12: Point of Care Tests: Clinical Use in 2017 in...Point of Care Tests: Clinical Use in 2017 Charlotte A. Gaydos, MS, MPH, DrPH Professor, Division of Infectious Diseases. Johns Hopkins](https://reader034.fdocuments.in/reader034/viewer/2022042104/5e823594edeb421cd63ca650/html5/thumbnails/12.jpg)
Atlas Genetics io™ System• Low cost instrument• All reagents are on the Cartridge
• Ambient storage >12 month shelf-life• Broad range of clinical sample types• Disposable cartridge for sample• Results provided as clear output• CE Marked (CT); FDA clinical trials
underway (CT/NG)• Electrochemical label released from
probe hybridized by nuclease enzyme
![Page 13: Point of Care Tests: Clinical Use in 2017 in...Point of Care Tests: Clinical Use in 2017 Charlotte A. Gaydos, MS, MPH, DrPH Professor, Division of Infectious Diseases. Johns Hopkins](https://reader034.fdocuments.in/reader034/viewer/2022042104/5e823594edeb421cd63ca650/html5/thumbnails/13.jpg)
Atlas Genetics io™ SystemPerformance Characteristics of Atlas Assay Compared to
Laboratory-Based NAAT Testing by Symptom Status
Number TruePositive
FalsePositive
Prevalence (%)
Sensitivity (%)
Specificity (%)
Initial results 284 26 3 10.2 83.9 98.8
AfterDiscordant Testing
284 28 3 9.9 92.9 98.8
Lea Widdice, DeAnna Owens, Barbara Silver, Mathilda Barnes, Perry Barnes, Laura Dize, Charlotte Gaydos,Cincinnati Children’s Hospital Medical Center, Johns Hopkins University Society for Adol Health and Medicine Annual Meet. March 8-11, 2017, New Orleans, LA.
![Page 14: Point of Care Tests: Clinical Use in 2017 in...Point of Care Tests: Clinical Use in 2017 Charlotte A. Gaydos, MS, MPH, DrPH Professor, Division of Infectious Diseases. Johns Hopkins](https://reader034.fdocuments.in/reader034/viewer/2022042104/5e823594edeb421cd63ca650/html5/thumbnails/14.jpg)
Mobi-NAAT Chlamydia Test / PCR Droplet PCR microfluidic platform / Smartphone
Droplet cartridge platform
02000400060008000
10000120001400016000
0 10 20AU
C F
luor
esce
nce
(AU
)Sample identification number
Shin DJ, et al. Mobile nucleic acid amplification testing (mobiNAAT) for Chlamydia trachomatis screening in hospital emergency department settings Sci Reports 2017 Jul 3;7(1):4495
![Page 15: Point of Care Tests: Clinical Use in 2017 in...Point of Care Tests: Clinical Use in 2017 Charlotte A. Gaydos, MS, MPH, DrPH Professor, Division of Infectious Diseases. Johns Hopkins](https://reader034.fdocuments.in/reader034/viewer/2022042104/5e823594edeb421cd63ca650/html5/thumbnails/15.jpg)
Mobi-NAAT Chlamydia Test / PCR Droplet PCR microfluidic platform / Smartphone
Shin DJ, et al. Mobile nucleic acid amplification testing (mobiNAAT) for Chlamydia trachomatis screening in hospital emergency department settings Sci Reports 2017 Jul 3;7(1):4495
![Page 16: Point of Care Tests: Clinical Use in 2017 in...Point of Care Tests: Clinical Use in 2017 Charlotte A. Gaydos, MS, MPH, DrPH Professor, Division of Infectious Diseases. Johns Hopkins](https://reader034.fdocuments.in/reader034/viewer/2022042104/5e823594edeb421cd63ca650/html5/thumbnails/16.jpg)
Shin DJ, et al. Mobile nucleic acid amplification testing (mobiNAAT) for Chlamydia trachomatis screening in hospital emergency department settings. Sci Reports 2017 Jul 3;7(1):4495
![Page 17: Point of Care Tests: Clinical Use in 2017 in...Point of Care Tests: Clinical Use in 2017 Charlotte A. Gaydos, MS, MPH, DrPH Professor, Division of Infectious Diseases. Johns Hopkins](https://reader034.fdocuments.in/reader034/viewer/2022042104/5e823594edeb421cd63ca650/html5/thumbnails/17.jpg)
Trichomonas vaginalis Diagnostics
Wet Preparation showing motile trichomonads
Electron microscope view of trichomonas on epithelial cell
Stained Trichomonas
• Wet Preparation• Culture• Affirm VPIII • OSOM POC
AmpliVue POCSolana POCAptimaT. vaginalis (ATV)Becton Dickinson (TVQ)
• NAAT Non-NAAT
![Page 18: Point of Care Tests: Clinical Use in 2017 in...Point of Care Tests: Clinical Use in 2017 Charlotte A. Gaydos, MS, MPH, DrPH Professor, Division of Infectious Diseases. Johns Hopkins](https://reader034.fdocuments.in/reader034/viewer/2022042104/5e823594edeb421cd63ca650/html5/thumbnails/18.jpg)
OSOM Rapid TV Antigen Test•Immunochromato-graphic •TV membrane proteins•Mouse antibodies•Latex beads/ capillary action
Huppert et al , JCM 2005; STI 2007:
Sensitivity 83-90%,Specificity 98-100%
![Page 19: Point of Care Tests: Clinical Use in 2017 in...Point of Care Tests: Clinical Use in 2017 Charlotte A. Gaydos, MS, MPH, DrPH Professor, Division of Infectious Diseases. Johns Hopkins](https://reader034.fdocuments.in/reader034/viewer/2022042104/5e823594edeb421cd63ca650/html5/thumbnails/19.jpg)
AmpliVue® Trichomonas HDA Assay
1) simple sample preparation with 1-step dilution/heating2) isothermal DNA amplification of target sequence specific to T. vaginalis by Helicase Dependent Amplificat.3) lateral-flow strip based colorimetric detection in a self-contained, disposable device. FDA clearedSensitivity 100%; specificity 98.2% vs. culture/wet prep. Vs. NAAT PPA: 87.2-90.1%
Gaydos et al. STD 2016
![Page 20: Point of Care Tests: Clinical Use in 2017 in...Point of Care Tests: Clinical Use in 2017 Charlotte A. Gaydos, MS, MPH, DrPH Professor, Division of Infectious Diseases. Johns Hopkins](https://reader034.fdocuments.in/reader034/viewer/2022042104/5e823594edeb421cd63ca650/html5/thumbnails/20.jpg)
Clinical performance of the Solana POC Trichomonas Assay from clinician-
collected vaginal swabs and female urines
HDA amplificationRecently FDA ClearedModerately ComplexGaydos et al. CDC STD meet. Atlanta Sept 2016
Sample Sensitivity Specificity
Swabs 89.7% 99.0%Urine 100% 98.9%
Compared to NAAT reference
Vaginal Sensitivity SpecificityAsym. 100% 98.9%Sympt. 98.6% 98.5%
Compared to wet prep/culture
TV prevalence swabs and/or urines 11.5%
![Page 21: Point of Care Tests: Clinical Use in 2017 in...Point of Care Tests: Clinical Use in 2017 Charlotte A. Gaydos, MS, MPH, DrPH Professor, Division of Infectious Diseases. Johns Hopkins](https://reader034.fdocuments.in/reader034/viewer/2022042104/5e823594edeb421cd63ca650/html5/thumbnails/21.jpg)
HSV POC Diagnostics
![Page 22: Point of Care Tests: Clinical Use in 2017 in...Point of Care Tests: Clinical Use in 2017 Charlotte A. Gaydos, MS, MPH, DrPH Professor, Division of Infectious Diseases. Johns Hopkins](https://reader034.fdocuments.in/reader034/viewer/2022042104/5e823594edeb421cd63ca650/html5/thumbnails/22.jpg)
• FDA-cleared for HSV in genital and oral lesions• The IsoAmp HSV has a test-to-result time of <1.5 hr.• Isothermal helicase-dependent amplification (HDA)
technique; no nucleic acid extraction• The rapid and simple characteristics of the IsoAmp
HSV assay make it potentially suitable for POC testing
The IsoAmp® HSV Assay (Biohelix Corp)
Lemieux et al. Expert Reviews Ltd. 437-443, 2012;
25 ulVTM
1 ml buffer
25 ul
25 ul Master mix
640 60 min
![Page 23: Point of Care Tests: Clinical Use in 2017 in...Point of Care Tests: Clinical Use in 2017 Charlotte A. Gaydos, MS, MPH, DrPH Professor, Division of Infectious Diseases. Johns Hopkins](https://reader034.fdocuments.in/reader034/viewer/2022042104/5e823594edeb421cd63ca650/html5/thumbnails/23.jpg)
Syphilis: Serologic DX requiresdetection of two types of
antibodies•Non-Treponemal RPR, VDRL •Treponemal FTA-abs, TPPA, Many new
automated, POC
Both test types have imperfect specificity•Reactive treponemal test cannot distinguish active from inactive infection
VDRL: Venereal Disease Research Laboratory
RPR: Rapid Plasma Reagin
![Page 24: Point of Care Tests: Clinical Use in 2017 in...Point of Care Tests: Clinical Use in 2017 Charlotte A. Gaydos, MS, MPH, DrPH Professor, Division of Infectious Diseases. Johns Hopkins](https://reader034.fdocuments.in/reader034/viewer/2022042104/5e823594edeb421cd63ca650/html5/thumbnails/24.jpg)
Treponemal Syphilis Tests: EIA/CIA/POC
Advantages:
• Automated and are cost saving for large volume laboratories
• May detect old untreated syphilis
Disadvantages:
• Less clinical experience with interpretation
• May be less sensitive than FTA-ab in early primary syphilis
![Page 25: Point of Care Tests: Clinical Use in 2017 in...Point of Care Tests: Clinical Use in 2017 Charlotte A. Gaydos, MS, MPH, DrPH Professor, Division of Infectious Diseases. Johns Hopkins](https://reader034.fdocuments.in/reader034/viewer/2022042104/5e823594edeb421cd63ca650/html5/thumbnails/25.jpg)
• Available in the U. S. - Immunochromatographic strip tests (ICS) • Syphilis Health Check – Trinity Biotech (FDA cleared, CLIA waived)
• Available Internationally• SD Bioline Syphilis 3.0 – Standard Diagnostics/ Alere• Determine Syphilis TP – Standard Diagnostics/ Alere
• Dual HIV/ Syphilis assays• Multiplo TP/HIV – Medmira Inc.• DPP HIV/ Syphilis – Chembio Diagnostics• SD Bioline HIV Syphilis Duo – Standard Diagnostics/ Alere
(WHO Premarket qualified)• INSTI™ HIV/Syphilis Multiplex Test - bioLytical• OnSite™HIV/Syphilis Ab Combo Rapid Test - CTK Biotech• CTK Biotech, Inc.• mChip Assay
Some Rapid POC Syphilis Tests
![Page 26: Point of Care Tests: Clinical Use in 2017 in...Point of Care Tests: Clinical Use in 2017 Charlotte A. Gaydos, MS, MPH, DrPH Professor, Division of Infectious Diseases. Johns Hopkins](https://reader034.fdocuments.in/reader034/viewer/2022042104/5e823594edeb421cd63ca650/html5/thumbnails/26.jpg)
Laboratory evaluations of syphilis rapid test performance 2010-2014
• Meta-analysis of 33 studies from POCs Sensitivity: 75.12% to 83.78% for blood
75.98% to 92.03% for serumSpecificity: 98.39% to 99.44% for blood
92.68% to 98.51% in serum
Bristow et al Sex Health 12: 119-125, 2015
PPV
![Page 27: Point of Care Tests: Clinical Use in 2017 in...Point of Care Tests: Clinical Use in 2017 Charlotte A. Gaydos, MS, MPH, DrPH Professor, Division of Infectious Diseases. Johns Hopkins](https://reader034.fdocuments.in/reader034/viewer/2022042104/5e823594edeb421cd63ca650/html5/thumbnails/27.jpg)
Uni-Gold Recombigen
OraQuick Advance
Clearview Complete
Clearview Stat PakINSTI
CLIA-WaivedPoint-of-Care
Rapid HIV Tests
HIV
![Page 28: Point of Care Tests: Clinical Use in 2017 in...Point of Care Tests: Clinical Use in 2017 Charlotte A. Gaydos, MS, MPH, DrPH Professor, Division of Infectious Diseases. Johns Hopkins](https://reader034.fdocuments.in/reader034/viewer/2022042104/5e823594edeb421cd63ca650/html5/thumbnails/28.jpg)
4th generation HIV-1/2 immunoassay
HIV-1/HIV-2 antibody differentiation immunoassay
(-)Negative for HIV-1 and HIV-2 antibodies
and p24 Ag(+)
HIV-1 +HIV-1 antibodies
detected Initiate care
(and viral load)
HIV-2 +HIV-2 antibodies
detected Initiate care
HIV-1&2 (-) or indeterminate
RNA
RNA (+)Acute HIV-1 infection
Initiate care
RNA (-)Negative for HIV-1
New HIV Diagnostic Algorithm
HIV-1 +/HIV-2 +HIV antibodies
detected
Branson BM, Mermin J. J Clin Vir 2011;52:S3-4; MMWR 62, June 21, 2013. CLSI 2011
Screen
Confirm
![Page 29: Point of Care Tests: Clinical Use in 2017 in...Point of Care Tests: Clinical Use in 2017 Charlotte A. Gaydos, MS, MPH, DrPH Professor, Division of Infectious Diseases. Johns Hopkins](https://reader034.fdocuments.in/reader034/viewer/2022042104/5e823594edeb421cd63ca650/html5/thumbnails/29.jpg)
HIV Antibody
0 10 20 30 40 50 60 70 80 90 100
HIV p24 Ag
Acute HIV Infection
HIV RNA (plasma)
IgMIgG
Eclipse Period
Infection undetectable
!
Modified after Busch et al. Am J Med. 1997
HIV Infection and Laboratory Markers
![Page 30: Point of Care Tests: Clinical Use in 2017 in...Point of Care Tests: Clinical Use in 2017 Charlotte A. Gaydos, MS, MPH, DrPH Professor, Division of Infectious Diseases. Johns Hopkins](https://reader034.fdocuments.in/reader034/viewer/2022042104/5e823594edeb421cd63ca650/html5/thumbnails/30.jpg)
Bio-Rad Geenius™
• HIV confirmation and differentiation in less than 30 minutes• 3 sample types : serum, plasma (5ul), whole blood (15 ul) • Software that uses a validated algorithm, Full traceability • Limited data on performance in the lab algorithm suggests comparable
to Mutlispot
Delaney et al CROI 2015 abstract #621
Supplemental assay -Confirmation and differentiation of HIV-1 and HIV-2 antibodies
![Page 31: Point of Care Tests: Clinical Use in 2017 in...Point of Care Tests: Clinical Use in 2017 Charlotte A. Gaydos, MS, MPH, DrPH Professor, Division of Infectious Diseases. Johns Hopkins](https://reader034.fdocuments.in/reader034/viewer/2022042104/5e823594edeb421cd63ca650/html5/thumbnails/31.jpg)
Alere Determine™HIV-1/2 Ag/Ab Combo
Method: Lateral flowTime to Results: 20 minutesStorage Conditions: 2 - 30°CShelf Life: 9 monthsSample Type: Serum/plasma/whole bloodDistinguishes Ag/Ab reactivity
• We do not know performance characteristics in the lab algorithm-Data collection is underway
• CLIA waived for whole blood
• Data from plasma suggests the assay detects infection ~ 3-5 days After instrumented Ag/Ab combo assays and possibly longer delayswith whole blood
Masciotra et al JCV 2013
![Page 32: Point of Care Tests: Clinical Use in 2017 in...Point of Care Tests: Clinical Use in 2017 Charlotte A. Gaydos, MS, MPH, DrPH Professor, Division of Infectious Diseases. Johns Hopkins](https://reader034.fdocuments.in/reader034/viewer/2022042104/5e823594edeb421cd63ca650/html5/thumbnails/32.jpg)
In a laboratory setting, test has an overall sensitivity of 92% to detect any stage of HIV-1 infection using sera specimens. It performs relatively well in detecting early HIV and may be beneficial as an initial screening in patients with a recent exposure to HIV.Additional testing in a laboratory setting remains mandatory as a proportion of acute HIV-1 infections are missed with this test.
Van Tienen et al. STI. Published Online First: doi:10.1136/sextrans-2016-052818
![Page 33: Point of Care Tests: Clinical Use in 2017 in...Point of Care Tests: Clinical Use in 2017 Charlotte A. Gaydos, MS, MPH, DrPH Professor, Division of Infectious Diseases. Johns Hopkins](https://reader034.fdocuments.in/reader034/viewer/2022042104/5e823594edeb421cd63ca650/html5/thumbnails/33.jpg)
Multiplex Real-Time PCR- Viral LoadPlasma 1mlQualitative Dx test from Whole blood~ 2hour run-timeAC power with potential for battery
Cepheid GeneXpert® System
Coming soon
![Page 34: Point of Care Tests: Clinical Use in 2017 in...Point of Care Tests: Clinical Use in 2017 Charlotte A. Gaydos, MS, MPH, DrPH Professor, Division of Infectious Diseases. Johns Hopkins](https://reader034.fdocuments.in/reader034/viewer/2022042104/5e823594edeb421cd63ca650/html5/thumbnails/34.jpg)
• Multiplex Real-Time PCR- Viral Load• 30 min (500-1000cp/ml), 60 min (50 cp/ml)• Qualitative Dx• Whole Blood or plasma• AC power and battery• Integrated disposable cartridge contains all reagents
for prep, amp & detection
Liat™ Analyzer Roche
![Page 35: Point of Care Tests: Clinical Use in 2017 in...Point of Care Tests: Clinical Use in 2017 Charlotte A. Gaydos, MS, MPH, DrPH Professor, Division of Infectious Diseases. Johns Hopkins](https://reader034.fdocuments.in/reader034/viewer/2022042104/5e823594edeb421cd63ca650/html5/thumbnails/35.jpg)
• Sample: 25 μL fingerstick whole blood• Sealed system• PCR• Results in 50 minutes• Data Matrix: Expiry QC, assay type, lot
Information• Kit shipped and stored at room temperature
Alere™ q HIV-1/2 Detect
• Built in battery • Simple procedure with built in
controls• Touch screen• Data storage of 1000 tests• Easily transportable, 17.2 lbs.
Alere™ q Analyzer
Alere™ Q System
![Page 36: Point of Care Tests: Clinical Use in 2017 in...Point of Care Tests: Clinical Use in 2017 Charlotte A. Gaydos, MS, MPH, DrPH Professor, Division of Infectious Diseases. Johns Hopkins](https://reader034.fdocuments.in/reader034/viewer/2022042104/5e823594edeb421cd63ca650/html5/thumbnails/36.jpg)
New Data For Time to Test Reactivity
• Desire to have time since infection/RNA reactive• Used same serconversion panel data and
performed new estimates for time since RNA reactivity
• Inter-test reactivity interval (ITRI) • Eclipse period simulated from published data• Why?
• Valuable to testing providers for interpreting negative HIV test results
• Counseling individuals on when to retest after an exposure.
Delaney et al CID, 2016 http://cid.oxfordjournals.org/content/early/2016/11/03/cid.ciw666.full.pdf?keytype=ref&ijkey=P9Yzswu8ePE5WwP
![Page 37: Point of Care Tests: Clinical Use in 2017 in...Point of Care Tests: Clinical Use in 2017 Charlotte A. Gaydos, MS, MPH, DrPH Professor, Division of Infectious Diseases. Johns Hopkins](https://reader034.fdocuments.in/reader034/viewer/2022042104/5e823594edeb421cd63ca650/html5/thumbnails/37.jpg)
Considerations for HIV POC Testing
• Locations/populations that lab testing is difficult or not feasibleBetter to use POC than no test
• POC assays continue to improve and have good sensitivity and specificity for established infections but…Be aware of assay limitations Provide informed counseling messagesOral Fluid assays will miss acute infections and
some early infections
1 Stekler et al, JCV 2013, 2 Luo et al JCV 2013
![Page 38: Point of Care Tests: Clinical Use in 2017 in...Point of Care Tests: Clinical Use in 2017 Charlotte A. Gaydos, MS, MPH, DrPH Professor, Division of Infectious Diseases. Johns Hopkins](https://reader034.fdocuments.in/reader034/viewer/2022042104/5e823594edeb421cd63ca650/html5/thumbnails/38.jpg)
• Of the 40 patients with AHI, 23 (57.5%) had a reactive STAT-VIEW rapid test. • Examining sensitivity of STAT-VIEW over course of AHI duration, probability of HIV detection was
75.5% at 5 weeks. • INSTI provided similar results with respect to proportion of reactive tests (62.5%), with probability
of HIV detection 85.0% at 5 weeks of infection. • Do not rely on a negative result to accurately exclude HIV infection within at least 5 weeks of
potential HIV exposure. Some utility in detecting HIV is observed 5–12 weeks after transmission.
Boukli et al. STI 2017 doi:10.1136/sextrans-2017-053131
![Page 39: Point of Care Tests: Clinical Use in 2017 in...Point of Care Tests: Clinical Use in 2017 Charlotte A. Gaydos, MS, MPH, DrPH Professor, Division of Infectious Diseases. Johns Hopkins](https://reader034.fdocuments.in/reader034/viewer/2022042104/5e823594edeb421cd63ca650/html5/thumbnails/39.jpg)
Of 1914 identified papers, 18 were included for the meta-analysis of diagnostic accuracy for HIV and syphilis. All diagnostic accuracy evaluation studies showed a very high sensitivity and specificity for HIV and a lower, yet adequate, sensitivity and specificity for syphilis, with some variation among types of test. Dual screening for HIV and syphilis was more cost effective than single rapid tests for HIV and syphilis and prevented more adverse pregnancy outcomes. Qualitative data suggested dual RDTs were highly acceptable to clients, who cited time to result, cost & requirement of a single finger prick as important characteristics of dual RDTs.
![Page 40: Point of Care Tests: Clinical Use in 2017 in...Point of Care Tests: Clinical Use in 2017 Charlotte A. Gaydos, MS, MPH, DrPH Professor, Division of Infectious Diseases. Johns Hopkins](https://reader034.fdocuments.in/reader034/viewer/2022042104/5e823594edeb421cd63ca650/html5/thumbnails/40.jpg)
Meta-analysis of the diagnostic accuracy of dual HIV/syphilis RDTs, stratified according to manufacturer.
Harriet D Gliddon et al. Sex Transm Infect doi:10.1136/sextrans-2016-053069©2017 by BMJ Publishing Group Ltd
ChemBio
SD Bioline
MedMira
SD Bioline by syphilis
MedMira by syphilis
ChemBio by syphilis
![Page 41: Point of Care Tests: Clinical Use in 2017 in...Point of Care Tests: Clinical Use in 2017 Charlotte A. Gaydos, MS, MPH, DrPH Professor, Division of Infectious Diseases. Johns Hopkins](https://reader034.fdocuments.in/reader034/viewer/2022042104/5e823594edeb421cd63ca650/html5/thumbnails/41.jpg)
Among 827 sexually active participants, 89% had been tested for HIV. • Most preferred by participants was home
rapid testing (46%), followed by standard-of-care (23%) and rapid testing in healthcare (20%) or community (7%)
• 73% of participants preferred rapid over non-rapid testing, and 56% preferred testing in non-healthcare settings rather than in healthcare settings.
![Page 42: Point of Care Tests: Clinical Use in 2017 in...Point of Care Tests: Clinical Use in 2017 Charlotte A. Gaydos, MS, MPH, DrPH Professor, Division of Infectious Diseases. Johns Hopkins](https://reader034.fdocuments.in/reader034/viewer/2022042104/5e823594edeb421cd63ca650/html5/thumbnails/42.jpg)
![Page 43: Point of Care Tests: Clinical Use in 2017 in...Point of Care Tests: Clinical Use in 2017 Charlotte A. Gaydos, MS, MPH, DrPH Professor, Division of Infectious Diseases. Johns Hopkins](https://reader034.fdocuments.in/reader034/viewer/2022042104/5e823594edeb421cd63ca650/html5/thumbnails/43.jpg)
Emergency Departments: Critical Venue HIV TestsFeasibility, Acceptability, and Accuracy
![Page 44: Point of Care Tests: Clinical Use in 2017 in...Point of Care Tests: Clinical Use in 2017 Charlotte A. Gaydos, MS, MPH, DrPH Professor, Division of Infectious Diseases. Johns Hopkins](https://reader034.fdocuments.in/reader034/viewer/2022042104/5e823594edeb421cd63ca650/html5/thumbnails/44.jpg)
96.4%
3.3% 0.2%
Correct Result?
DefinitelyCorrect
91.7%
8.0% 0.2%
Trust the Result?
VeryMuch
99%
0.7%0.2%
Ease of Performance
Easy
Somewhat EasyNot Easy
85%
11.8%3.1%
Would Test Themselves if Available OTC
Definitely
Probably
Would NotTest
473/955 (49.5%) consented; Median age was 41 years, 59.6 % were female, 74.8% African American
![Page 45: Point of Care Tests: Clinical Use in 2017 in...Point of Care Tests: Clinical Use in 2017 Charlotte A. Gaydos, MS, MPH, DrPH Professor, Division of Infectious Diseases. Johns Hopkins](https://reader034.fdocuments.in/reader034/viewer/2022042104/5e823594edeb421cd63ca650/html5/thumbnails/45.jpg)
Objectives
1. To discuss current molecular tests and update new POC tests in the pipeline
2. To demonstrate different venues for STI testing outside the clinic, OTC or home STI testing
3. To mention impact of POC testing-advantages and barriers
![Page 46: Point of Care Tests: Clinical Use in 2017 in...Point of Care Tests: Clinical Use in 2017 Charlotte A. Gaydos, MS, MPH, DrPH Professor, Division of Infectious Diseases. Johns Hopkins](https://reader034.fdocuments.in/reader034/viewer/2022042104/5e823594edeb421cd63ca650/html5/thumbnails/46.jpg)
Female Preference for Type Specimen Collection
Gaydos et al. STD
Self-collected vaginal swabs are acceptable and preferred over urine and cx to women
![Page 47: Point of Care Tests: Clinical Use in 2017 in...Point of Care Tests: Clinical Use in 2017 Charlotte A. Gaydos, MS, MPH, DrPH Professor, Division of Infectious Diseases. Johns Hopkins](https://reader034.fdocuments.in/reader034/viewer/2022042104/5e823594edeb421cd63ca650/html5/thumbnails/47.jpg)
Focus Group and Clinic Questionnaire about Near Patient Tests (N =371)
Specimen Type Preference
Percent
Cervical 15.4%Vaginal 50.9%Urine 33.7%
Willingness to Wait
Percent
20 min 59.0%40 min 20.8%60 min 10.8%90 min 9.4%Willingness to Pay Percent
$10 46.6%$20 31.0%$30 10.8%$40 2.7%$50 8.9%
80.9%
3.0%16.1%
easy hard OK
Self –collected vaginal swabs
![Page 48: Point of Care Tests: Clinical Use in 2017 in...Point of Care Tests: Clinical Use in 2017 Charlotte A. Gaydos, MS, MPH, DrPH Professor, Division of Infectious Diseases. Johns Hopkins](https://reader034.fdocuments.in/reader034/viewer/2022042104/5e823594edeb421cd63ca650/html5/thumbnails/48.jpg)
Use of POC Outside the ClinicEmergency Department• 80% of women would “definitely” test themselves at
home if a TV test were available OTC
Pharmacy• Pharmacists are ranked among the most trusted
health care professionals; are accessible 24/7
Internet Iwantthekit Internet Smart Phone
![Page 49: Point of Care Tests: Clinical Use in 2017 in...Point of Care Tests: Clinical Use in 2017 Charlotte A. Gaydos, MS, MPH, DrPH Professor, Division of Infectious Diseases. Johns Hopkins](https://reader034.fdocuments.in/reader034/viewer/2022042104/5e823594edeb421cd63ca650/html5/thumbnails/49.jpg)
Emergency Department Kiosk-facilitated POC OSOM Trichomonas Self-testing
n= 150 %OSOM Prevalence 16.8%Wet Mount Prevalence
9.8%
100% reading accuracy for negative results96% reading accuracy for positive results
![Page 50: Point of Care Tests: Clinical Use in 2017 in...Point of Care Tests: Clinical Use in 2017 Charlotte A. Gaydos, MS, MPH, DrPH Professor, Division of Infectious Diseases. Johns Hopkins](https://reader034.fdocuments.in/reader034/viewer/2022042104/5e823594edeb421cd63ca650/html5/thumbnails/50.jpg)
Emergency contraception patients were invited to order a home collection kit for STI testing
Questionnaires for acceptability
Sexual Health 12:472-479, 2015
Pharmacy Testing Acceptability of pharmacy and home based testing
Pharmacy participantsN= 38
IWTK participants kit return (N =81
No IWTK kit return (N=209)
Pharmacies should offer STI tests
Yes 97% 92.6% 90.9%
Likelihood to use Home kit from pharmacy if free or insurance
VerylikelyLikely
81.6%
10.5%
80.2%
18.5%
77.0%
19.1%
![Page 51: Point of Care Tests: Clinical Use in 2017 in...Point of Care Tests: Clinical Use in 2017 Charlotte A. Gaydos, MS, MPH, DrPH Professor, Division of Infectious Diseases. Johns Hopkins](https://reader034.fdocuments.in/reader034/viewer/2022042104/5e823594edeb421cd63ca650/html5/thumbnails/51.jpg)
• Order a kit online & select Rx clinic
• Kit mailed to home • Collect sample at home• Mail kit to lab• Text or Email sent for when results are ready • Password protected account; obtains results
on line; attends clinic of choice treatment
Internet Outside the Clinic: IWTK
www.iwantthekit.org
Since 2004: Screened 7212 Women, 1313 F rectal 3939 Males; 868 M rectal
![Page 52: Point of Care Tests: Clinical Use in 2017 in...Point of Care Tests: Clinical Use in 2017 Charlotte A. Gaydos, MS, MPH, DrPH Professor, Division of Infectious Diseases. Johns Hopkins](https://reader034.fdocuments.in/reader034/viewer/2022042104/5e823594edeb421cd63ca650/html5/thumbnails/52.jpg)
![Page 53: Point of Care Tests: Clinical Use in 2017 in...Point of Care Tests: Clinical Use in 2017 Charlotte A. Gaydos, MS, MPH, DrPH Professor, Division of Infectious Diseases. Johns Hopkins](https://reader034.fdocuments.in/reader034/viewer/2022042104/5e823594edeb421cd63ca650/html5/thumbnails/53.jpg)
Women can perform a self TV test at home
![Page 54: Point of Care Tests: Clinical Use in 2017 in...Point of Care Tests: Clinical Use in 2017 Charlotte A. Gaydos, MS, MPH, DrPH Professor, Division of Infectious Diseases. Johns Hopkins](https://reader034.fdocuments.in/reader034/viewer/2022042104/5e823594edeb421cd63ca650/html5/thumbnails/54.jpg)
Trichomonas Home Test AnalysisQuestion, N = 92 Easy Somewhat Easy Not Easy
How easy was it for you to collect the vaginal specimen correctly?
88 (95.6%) 3 (3.3% 1 (1.1%)
How easy was it for you to read the test strip and interpret (tell) the result?
84 (91.3%) 6 (6.5%) 2 (2.2%)
Overall, how easy was it for you to perform the test?
85 (92.4%) 5 (5.4%) 1 (1.1%)
Definitely Correct
Probably correct Not Correct
Do you believe that the rapid trichomonas test result was correct for the sample that you collected?
52 (56.5%) 39 (42.4%) 1 (1.1%)
![Page 55: Point of Care Tests: Clinical Use in 2017 in...Point of Care Tests: Clinical Use in 2017 Charlotte A. Gaydos, MS, MPH, DrPH Professor, Division of Infectious Diseases. Johns Hopkins](https://reader034.fdocuments.in/reader034/viewer/2022042104/5e823594edeb421cd63ca650/html5/thumbnails/55.jpg)
Objectives
1. To discuss current molecular tests and update new POC tests in the pipeline
2. To demonstrate different venues for STI testing outside the clinic, OTC or home STI testing
3. To mention impact of POC testing-advantages and barriers
![Page 56: Point of Care Tests: Clinical Use in 2017 in...Point of Care Tests: Clinical Use in 2017 Charlotte A. Gaydos, MS, MPH, DrPH Professor, Division of Infectious Diseases. Johns Hopkins](https://reader034.fdocuments.in/reader034/viewer/2022042104/5e823594edeb421cd63ca650/html5/thumbnails/56.jpg)
• Immediate treatment of positivepatients
• Expedite appropriate therapy• Reduce empirical treatment• Lower risk of antibiotic resistance• Improve compliance / minimize
loss to follow-up• Decrease forward transmission• Lower risk of sequelae• Improve the patient experience
Key Applications POC TestsSexually Transmitted Infections
![Page 57: Point of Care Tests: Clinical Use in 2017 in...Point of Care Tests: Clinical Use in 2017 Charlotte A. Gaydos, MS, MPH, DrPH Professor, Division of Infectious Diseases. Johns Hopkins](https://reader034.fdocuments.in/reader034/viewer/2022042104/5e823594edeb421cd63ca650/html5/thumbnails/57.jpg)
Barriers to Implementation • Financial viability• Money for instruments and consumables • Obtaining CLIA certificate• Validating the new test(s)• Policies and procedures (training manuals)• Operator training (recertification, proficiency)• Getting results into the EMR (interface- $7K?)• Space• Work Flow Disruption• Billing and Reimbursement
![Page 58: Point of Care Tests: Clinical Use in 2017 in...Point of Care Tests: Clinical Use in 2017 Charlotte A. Gaydos, MS, MPH, DrPH Professor, Division of Infectious Diseases. Johns Hopkins](https://reader034.fdocuments.in/reader034/viewer/2022042104/5e823594edeb421cd63ca650/html5/thumbnails/58.jpg)
Conclusions
• POCTs in primary/STI care and perhaps OTC have great potential
• But there are barriers to successful implementation that need to be overcome which can be costly, time consuming, and require learning new skill sets
• Better POC tests are coming; the future is promising
![Page 59: Point of Care Tests: Clinical Use in 2017 in...Point of Care Tests: Clinical Use in 2017 Charlotte A. Gaydos, MS, MPH, DrPH Professor, Division of Infectious Diseases. Johns Hopkins](https://reader034.fdocuments.in/reader034/viewer/2022042104/5e823594edeb421cd63ca650/html5/thumbnails/59.jpg)
Acknowledgements•Anne Rompalo•Mary Jett-Goheen•Mathilda Barnes •Justin Hardick•Jeff Holden •Laura Dize•Perry Barnes•Barbara Silver
We are trying to POINT the WAY for POC Tests
![Page 60: Point of Care Tests: Clinical Use in 2017 in...Point of Care Tests: Clinical Use in 2017 Charlotte A. Gaydos, MS, MPH, DrPH Professor, Division of Infectious Diseases. Johns Hopkins](https://reader034.fdocuments.in/reader034/viewer/2022042104/5e823594edeb421cd63ca650/html5/thumbnails/60.jpg)
![Page 61: Point of Care Tests: Clinical Use in 2017 in...Point of Care Tests: Clinical Use in 2017 Charlotte A. Gaydos, MS, MPH, DrPH Professor, Division of Infectious Diseases. Johns Hopkins](https://reader034.fdocuments.in/reader034/viewer/2022042104/5e823594edeb421cd63ca650/html5/thumbnails/61.jpg)
Novel Microdevices
Self-contained Microfluidic Cartridge
Insert chip into device
Transfer sample into chip, start
On-chip DNA purification
On-chip DNA amplification
Detection and result display
Time to Result <20 minutes
Hands-on time <2 minutes
<1 <1 2 15 <1
Hand-held Assay Automation Instrument
• Sensitivity equivalent to lab qPCR test• Assay was able to detect <5 EB of
Chlamydia• Highly specific to only Chlamydia strains• Preclinical evaluation using clinical samples
underway.
![Page 62: Point of Care Tests: Clinical Use in 2017 in...Point of Care Tests: Clinical Use in 2017 Charlotte A. Gaydos, MS, MPH, DrPH Professor, Division of Infectious Diseases. Johns Hopkins](https://reader034.fdocuments.in/reader034/viewer/2022042104/5e823594edeb421cd63ca650/html5/thumbnails/62.jpg)
Evolution of Syphilis Test
Traditional syphilis tests - Manual
Automated Test platforms
Rapid syphilis test • Treponemal
• Treponemal
• Nontreponemal• Treponemal
![Page 63: Point of Care Tests: Clinical Use in 2017 in...Point of Care Tests: Clinical Use in 2017 Charlotte A. Gaydos, MS, MPH, DrPH Professor, Division of Infectious Diseases. Johns Hopkins](https://reader034.fdocuments.in/reader034/viewer/2022042104/5e823594edeb421cd63ca650/html5/thumbnails/63.jpg)
Self-Testing Instruction Guide
![Page 64: Point of Care Tests: Clinical Use in 2017 in...Point of Care Tests: Clinical Use in 2017 Charlotte A. Gaydos, MS, MPH, DrPH Professor, Division of Infectious Diseases. Johns Hopkins](https://reader034.fdocuments.in/reader034/viewer/2022042104/5e823594edeb421cd63ca650/html5/thumbnails/64.jpg)
• All 5 commercial NAAT assays have approval for clinician-collected and self-collected vaginal swabs for CT/NG
• Sensitivities and specificities 94.5%-100%
• Self-collected vaginal swabs are not FDA cleared for home collection for mailing but used in research studies
Self-Collected Vaginal Swabs
(Aptima, M-2000, ProbeTech Qx Amplified DNA, Cobas 4800, Cepheid)
Schachter STD 2005; Gaydos JCM 2010; Taylor JCM 2011; Van Der Pol STD 2012; Van Der Pol STD 2013; Gaydos JCM 2013
![Page 65: Point of Care Tests: Clinical Use in 2017 in...Point of Care Tests: Clinical Use in 2017 Charlotte A. Gaydos, MS, MPH, DrPH Professor, Division of Infectious Diseases. Johns Hopkins](https://reader034.fdocuments.in/reader034/viewer/2022042104/5e823594edeb421cd63ca650/html5/thumbnails/65.jpg)
2805 men with syphilis contributing 11, 714 person-years of follow-up, 423 (15.1%) acquired HIV; annual incidence was 3.61% (95% CI, 3.27%, 3.97%).
HIV incidence was high among: MSM (5.56%, 95% CI, 5.02%–6.13%); males with secondary compared with primary syphilis (4.10% vs 2.64%, P < .0001); and males diagnosed with another bacterial STD after syphilis (7.89%, 95% CI, 6.62%–9.24%).
Hazard Ratio for MSM in multivariate analysis was 8.88
CID July 15, 2015
![Page 66: Point of Care Tests: Clinical Use in 2017 in...Point of Care Tests: Clinical Use in 2017 Charlotte A. Gaydos, MS, MPH, DrPH Professor, Division of Infectious Diseases. Johns Hopkins](https://reader034.fdocuments.in/reader034/viewer/2022042104/5e823594edeb421cd63ca650/html5/thumbnails/66.jpg)
Clinician Collected Vaginal or Cervical vs. Self-Collected Vaginal Swabs
Aptima M-2000 ProbeTechQx Amplified DNA
Cobas4800
GenXPert
CT PVS/CVS PVS/CVSSymptomat.
PVS/CxSwab
PVS vsCxSwab
PVS/CxSwab
Sensitivity 96.7/96.6% 97.7/92.5% 96.5/91.3% 94.5% 98.7/97.4%
Specificity 97.6/97.1% 99.9/98.8% 99.2/98.3% 99.5% 99.4/99.6%
NGSensitivity 98.7/96.2% 96.7/96.8% 100/98.5% 95.3% 100/100%
Specificity 99.6/99.4% 99.7/99.9% 99.1/99.7% 99.9% 99.9/100%
Schachter STD 2005; Gaydos JCM 2010; Taylor JCM 2011; Van Der Pol STD 2012; Van Der Pol STD 2013; Gaydos JCM 2013
![Page 67: Point of Care Tests: Clinical Use in 2017 in...Point of Care Tests: Clinical Use in 2017 Charlotte A. Gaydos, MS, MPH, DrPH Professor, Division of Infectious Diseases. Johns Hopkins](https://reader034.fdocuments.in/reader034/viewer/2022042104/5e823594edeb421cd63ca650/html5/thumbnails/67.jpg)
0
20
40
60
80
100
Collect OwnSpecimen
Vag swabSafe
Female Questionnaire Results:Self Collection Vaginal Swabs
90.9% 94.5%
0.00
20.00
40.00
60.00
80.00
100.00
Collection Easyto Very Easy
InstructionsEasy to Very
Easy
Use Internet-based SAS
again
Gaydos et al. STD
![Page 68: Point of Care Tests: Clinical Use in 2017 in...Point of Care Tests: Clinical Use in 2017 Charlotte A. Gaydos, MS, MPH, DrPH Professor, Division of Infectious Diseases. Johns Hopkins](https://reader034.fdocuments.in/reader034/viewer/2022042104/5e823594edeb421cd63ca650/html5/thumbnails/68.jpg)
Male Questionnaire ResultsHome collection (N = 501)
0.0%
20.0%
40.0%
60.0%
80.0%
100.0%
Collection Easy toVery Easy
Instructions Easy toVery Easy
Use Internet-basedSAS again
Penile Swab89.8% 94.0% 91.4%
Urine95.3%
Chai et al . STD
![Page 69: Point of Care Tests: Clinical Use in 2017 in...Point of Care Tests: Clinical Use in 2017 Charlotte A. Gaydos, MS, MPH, DrPH Professor, Division of Infectious Diseases. Johns Hopkins](https://reader034.fdocuments.in/reader034/viewer/2022042104/5e823594edeb421cd63ca650/html5/thumbnails/69.jpg)
Why do POCTs OCT?
• Improve patient satisfaction (privacy)• Treat patients before infecting others• Increase risk reduction• Decrease interval of disease spread• Improve treatment efficiency for the
patient• Improve medical outcomes for sequelae
![Page 70: Point of Care Tests: Clinical Use in 2017 in...Point of Care Tests: Clinical Use in 2017 Charlotte A. Gaydos, MS, MPH, DrPH Professor, Division of Infectious Diseases. Johns Hopkins](https://reader034.fdocuments.in/reader034/viewer/2022042104/5e823594edeb421cd63ca650/html5/thumbnails/70.jpg)
STI: 2013; 89:88-89
Netherlands compared three CE-marked POC tests (one enzymatic and other two antigen tests) for diagnostic performance in a high CT-prevalence population (11%), compared with NAATs over 8-months The sensitivity of the tests was disappointing, and ranged from 12% to 27% in 772 women tested
van Dommelen et al. Alarmingly poor performance in Chlamydia trachomatis point-of-care testing. Sex Transm Infect 2010;86:355–9.
![Page 71: Point of Care Tests: Clinical Use in 2017 in...Point of Care Tests: Clinical Use in 2017 Charlotte A. Gaydos, MS, MPH, DrPH Professor, Division of Infectious Diseases. Johns Hopkins](https://reader034.fdocuments.in/reader034/viewer/2022042104/5e823594edeb421cd63ca650/html5/thumbnails/71.jpg)
• Favorable POCTs (Rapid, Easy to read, Simple to use)• Home testing acceptable – better privacy• Clinic-based- definitive results & immediate treatment• Barriers- cost and ability to read and perform tests• Hispanic patients questioned home test reliability,
wanted bi-lingual instructions
POC tests for STIs: What do “end users” want? (N=58, 5 focus groups)
)
Rompalo et al. Sexual Health 2013;10:541-545
![Page 72: Point of Care Tests: Clinical Use in 2017 in...Point of Care Tests: Clinical Use in 2017 Charlotte A. Gaydos, MS, MPH, DrPH Professor, Division of Infectious Diseases. Johns Hopkins](https://reader034.fdocuments.in/reader034/viewer/2022042104/5e823594edeb421cd63ca650/html5/thumbnails/72.jpg)
Self-Collection of Urogenital Samples is Acceptable & AccurateSelf-collected vaginal swabs are acceptable and preferred (30.5%) over urine (26.2%) and cx to womenAll 5 commercial companies have clearance to test self-collected vaginal swabs (as well as urine samples)FDA trial surveys by 2,009 females
Question %Written instructions were understood 99.25%Diagrams helpful 96.27%Successfully completed 98.26$No preference 29.87%
Gaydos et al. JCM 43:3236–3243, 2010
![Page 73: Point of Care Tests: Clinical Use in 2017 in...Point of Care Tests: Clinical Use in 2017 Charlotte A. Gaydos, MS, MPH, DrPH Professor, Division of Infectious Diseases. Johns Hopkins](https://reader034.fdocuments.in/reader034/viewer/2022042104/5e823594edeb421cd63ca650/html5/thumbnails/73.jpg)
Can a pharmacist perform a POC test for STIs in a pharmacy?
Pharmacists are ranked among the most trusted health care professionalsThese healthcare professionals are easily accessible 24/7 Nearly 60,000 community pharmacies in the US Approximately 18% of these pharmacies have CLIA-waived status and can perform any of the approximately 120 CLIA-waived tests Clinical Chemistry 62:679-683, 2016
![Page 74: Point of Care Tests: Clinical Use in 2017 in...Point of Care Tests: Clinical Use in 2017 Charlotte A. Gaydos, MS, MPH, DrPH Professor, Division of Infectious Diseases. Johns Hopkins](https://reader034.fdocuments.in/reader034/viewer/2022042104/5e823594edeb421cd63ca650/html5/thumbnails/74.jpg)
![Page 75: Point of Care Tests: Clinical Use in 2017 in...Point of Care Tests: Clinical Use in 2017 Charlotte A. Gaydos, MS, MPH, DrPH Professor, Division of Infectious Diseases. Johns Hopkins](https://reader034.fdocuments.in/reader034/viewer/2022042104/5e823594edeb421cd63ca650/html5/thumbnails/75.jpg)
![Page 76: Point of Care Tests: Clinical Use in 2017 in...Point of Care Tests: Clinical Use in 2017 Charlotte A. Gaydos, MS, MPH, DrPH Professor, Division of Infectious Diseases. Johns Hopkins](https://reader034.fdocuments.in/reader034/viewer/2022042104/5e823594edeb421cd63ca650/html5/thumbnails/76.jpg)
36.7 million [34.0 million – 39.8 million] 31.8 million [30.1 million – 33.7 million]16.0 million [15.2 million – 16.9 million]3.2 million [2.9 million – 3.5 million]
2.1 million [1.9 million – 2.4 million]1.9 million [1.7 million – 2.1 million] 240 000 [210 000 – 280 000]
1.1 million [940 000 – 1.3 million]1.0 million [1.2 million – 1.5 million] 190 000 [170 000 – 220 000]
Number of people living with HIV in 2015
People newly infected with HIV in 2015
AIDS deaths in 2015
TotalAdults
WomenChildren (<15 years)
TotalAdults
Children (<15 years)
TotalAdults
Children (<15 years)
Global summary: AIDS epidemic
Source: UNAIDS/WHO estimates.
![Page 77: Point of Care Tests: Clinical Use in 2017 in...Point of Care Tests: Clinical Use in 2017 Charlotte A. Gaydos, MS, MPH, DrPH Professor, Division of Infectious Diseases. Johns Hopkins](https://reader034.fdocuments.in/reader034/viewer/2022042104/5e823594edeb421cd63ca650/html5/thumbnails/77.jpg)
Solana Results Vaginal Swabs for TV vaginal swabs and urines
(N=1044)Vaginal Swabs Sensitivity SpecificityAsymptomatic 100% 98.9%Symptomatic 98.6% 98.5%
Compared to FDA-composite reference method wet preparation & culture
Urine Sensitivity SpecificityAsymptomatic 98.0% 98.4%Symptomatic 92.9% 97.9%
TV prevalence swabs and/or urines 11.5%
![Page 78: Point of Care Tests: Clinical Use in 2017 in...Point of Care Tests: Clinical Use in 2017 Charlotte A. Gaydos, MS, MPH, DrPH Professor, Division of Infectious Diseases. Johns Hopkins](https://reader034.fdocuments.in/reader034/viewer/2022042104/5e823594edeb421cd63ca650/html5/thumbnails/78.jpg)
Second generation treponemal tests utilize recombinant protein antigens
• Recombinant T. pallidum antigens developed in the 1980sHigh test specificity Solid-phase immunoassays High test sensitivity
• Several EIAs, CIAs, and MFIs have become commercially available
• Reverse Algorithm testinghas been introduced
![Page 79: Point of Care Tests: Clinical Use in 2017 in...Point of Care Tests: Clinical Use in 2017 Charlotte A. Gaydos, MS, MPH, DrPH Professor, Division of Infectious Diseases. Johns Hopkins](https://reader034.fdocuments.in/reader034/viewer/2022042104/5e823594edeb421cd63ca650/html5/thumbnails/79.jpg)
Syphilis serologicscreening algorithms
EIA/CIA/POC
EIA/CIA+
Quantitative RPR
RPR+Syphilis(past or present)
RPR-
TP-PA
TP-PA+Syphilis (past or present)
TP-PA-Syphilis unlikely
EIA/CIA-Quantitative
RPR
RPR+
TP-PA or other trep. test
TP-PA+Syphilis (past or present)
TP-PA-Syphilis unlikely
RPR-
Traditional Reverse sequence
If at risk for syphilis, repeat RPR in several weeks
Evaluate clinically
CDC recommende algorithm for reverse sequence syphilis screening followed by nontreponemal tes confirmation
![Page 80: Point of Care Tests: Clinical Use in 2017 in...Point of Care Tests: Clinical Use in 2017 Charlotte A. Gaydos, MS, MPH, DrPH Professor, Division of Infectious Diseases. Johns Hopkins](https://reader034.fdocuments.in/reader034/viewer/2022042104/5e823594edeb421cd63ca650/html5/thumbnails/80.jpg)
Positive predictive values of the immunochromatographic strip test
at various syphilis prevalences
![Page 81: Point of Care Tests: Clinical Use in 2017 in...Point of Care Tests: Clinical Use in 2017 Charlotte A. Gaydos, MS, MPH, DrPH Professor, Division of Infectious Diseases. Johns Hopkins](https://reader034.fdocuments.in/reader034/viewer/2022042104/5e823594edeb421cd63ca650/html5/thumbnails/81.jpg)
•Rapid qualitative screening for human TP antibodies
• Results in 10 minutes; 2 steps; room temperature
• 98% agreement to other treponemal tests
• Serum, plasma, whole blood or finger-stick
POC Syphilis Health CheckTM
Syphilis Antibody Rapid Immunochromatographic Test
Negative: 1 colored band in control areaPositive: Colored bands in testarea and control areaInconclusive: No distinct color bands in either area
FDA ClearedCLIA Waived
![Page 82: Point of Care Tests: Clinical Use in 2017 in...Point of Care Tests: Clinical Use in 2017 Charlotte A. Gaydos, MS, MPH, DrPH Professor, Division of Infectious Diseases. Johns Hopkins](https://reader034.fdocuments.in/reader034/viewer/2022042104/5e823594edeb421cd63ca650/html5/thumbnails/82.jpg)
http://www.alere.co.uk/sexual-health/alere-determinetm-syphilis-tp-13/product-listing.htm.
DetectsAntibodies to Treponema pallidum Recombinant TP (15kDa,
17kDa) antigens used as captures and detectorsRapid
Provides accurate and reliable results in 15 minutesConvenient
No refrigeration required (storage 2-30°C)No power or water source is needed to run test
FlexibleUses serum, plasma or whole blood by venipuncture or
finger prick
Standard Diagnostics-Alere Determine™ Syphilis TP POC
![Page 83: Point of Care Tests: Clinical Use in 2017 in...Point of Care Tests: Clinical Use in 2017 Charlotte A. Gaydos, MS, MPH, DrPH Professor, Division of Infectious Diseases. Johns Hopkins](https://reader034.fdocuments.in/reader034/viewer/2022042104/5e823594edeb421cd63ca650/html5/thumbnails/83.jpg)
DPP® HIV-Syphilis Assay
• Chembio Diagnostic Systems has developed a dual HIV 1/2 and Syphilis Treponemal antibodies POC test (Dual Path Platform (DPP®) technology)
• Immunochromatographic rapid screening POC test• Fingerstick whole blood, venous whole blood, serum,
and plasma
http://www.youtube.com/watch?x-yt-cl=68561176&feature=player_embedded&v=DE4Wxy4byQE&x-yt-ts=1401912551
Video whole Blood Sample:
http://chembio.com/products/human-diagnostics/dpp-hivsyphilis-assay.
![Page 84: Point of Care Tests: Clinical Use in 2017 in...Point of Care Tests: Clinical Use in 2017 Charlotte A. Gaydos, MS, MPH, DrPH Professor, Division of Infectious Diseases. Johns Hopkins](https://reader034.fdocuments.in/reader034/viewer/2022042104/5e823594edeb421cd63ca650/html5/thumbnails/84.jpg)
SD BIOLINE HIV Syphilis Duo
• SD BIOLINE HIV/Syphilis Duo test is a solid phase immunochromatographic assay
• Qualitative detection of antibodies to all isotypes(IgG, IgM, and IgA) specific to HIV-1/2 and/or Treponema palladium(TP)
• Serum, plasma, or whole blood
• 1-30℃ for 24 months
http://www.standardia.com
![Page 85: Point of Care Tests: Clinical Use in 2017 in...Point of Care Tests: Clinical Use in 2017 Charlotte A. Gaydos, MS, MPH, DrPH Professor, Division of Infectious Diseases. Johns Hopkins](https://reader034.fdocuments.in/reader034/viewer/2022042104/5e823594edeb421cd63ca650/html5/thumbnails/85.jpg)
http://www.medmira.com/images/uploads/MPSIABPM0001EN_Rev_0_1_Multiplo_TPHIV_Product_Sheet_(English).pdf
18 month shelf-life at 2-30°CNo refrigeration or cold chain requiredNo timers requiredResults are easy to interpretNo specialized equipment required
3 minute test procedure
Whole blood, serum or plasma specimens
No specialized training required
Built-in procedural and reagent control line
![Page 86: Point of Care Tests: Clinical Use in 2017 in...Point of Care Tests: Clinical Use in 2017 Charlotte A. Gaydos, MS, MPH, DrPH Professor, Division of Infectious Diseases. Johns Hopkins](https://reader034.fdocuments.in/reader034/viewer/2022042104/5e823594edeb421cd63ca650/html5/thumbnails/86.jpg)
Trichomonas Home Test Analysis
Question, N = 92 Trust very much
Trust Somewhat Do Not Trust
How much do you trust the result of the rapid trichomonas test that you collected and tested?
60 (65.2%) 31 (33.7%) 1 (1.1%)
DefinitelyTest
Probably Test Not Test
Would you test yourself at home for trichomonas if the rapid trichomonas test were available over-the-counter?
77 (83.7%) 14 (15.2%) 1 (1.1%)
$10 $20 $30What is the maximum price you would pay to purchase a rapid trichomonas test over-the-counter, if available?
42 (45.6%) 37 (40.2%) 3 (14.1%)
![Page 87: Point of Care Tests: Clinical Use in 2017 in...Point of Care Tests: Clinical Use in 2017 Charlotte A. Gaydos, MS, MPH, DrPH Professor, Division of Infectious Diseases. Johns Hopkins](https://reader034.fdocuments.in/reader034/viewer/2022042104/5e823594edeb421cd63ca650/html5/thumbnails/87.jpg)
Total: 36.7 million [34.0 million – 39.8 million]
Western & Central Europe
900 000[830 000 – 1.0 million]
Middle East & North Africa300 000
[250 000 – 360 000]
Sub-Saharan Africa23.5 million
[22.1 million – 24.8 million]
Eastern Europe & Central Asia1.4 million
[1.1 million – 1.8 million]
South & South-East Asia4.0 million
[3.1 million – 5.2 million]
Oceania53 000
[47 000 – 60 000]
North America1.4 million
[1.1 million – 2.0 million]
Latin America1.4 million
[1.1 million – 1.7 million]
East Asia830 000
[590 000 – 1.2 million]Caribbean230 000
[200 000 – 250 000]
Adults and Children Living with HIV
People newly infected with HIV in 2015: 2.1 M; AIDS deaths in 2015: 1.1 M
![Page 88: Point of Care Tests: Clinical Use in 2017 in...Point of Care Tests: Clinical Use in 2017 Charlotte A. Gaydos, MS, MPH, DrPH Professor, Division of Infectious Diseases. Johns Hopkins](https://reader034.fdocuments.in/reader034/viewer/2022042104/5e823594edeb421cd63ca650/html5/thumbnails/88.jpg)
Chlamydia trachomatis and Neisseria gonorrhoeae
Old: Culture and staining. New: PCR and other nucleic acid amplification tests (NAATs)
![Page 89: Point of Care Tests: Clinical Use in 2017 in...Point of Care Tests: Clinical Use in 2017 Charlotte A. Gaydos, MS, MPH, DrPH Professor, Division of Infectious Diseases. Johns Hopkins](https://reader034.fdocuments.in/reader034/viewer/2022042104/5e823594edeb421cd63ca650/html5/thumbnails/89.jpg)
What about the Small Laboratory?
BD MAXBy Becton Dickinson
• BD MAX can be used for chlamydia, gonorrhea, and trichomonas and for diagnosis of vaginitis
1. Collect 2. Transfer 3. Insert 4. Detect
• Gene Xpert by Cepheid can be used for chlamydia gonorrhea and trichomonas (90 min.)